Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Tetra-modality Bladder Preservation for Muscle-invasive Bladder Cancer
NCT06686381Phase 2Recruiting
- Sponsor
- American University of Beirut Medical Center
- Start
- Jun 2025
- Primary completion
- Aug 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in muscle-invasive bladder cancer (MIBC), sponsored by American University of Beirut Medical Center. Started Jun 2025; status: recruiting.
02
Drugs
avelumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06686381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686381.